Today looks good. Hopefully, we gather momentum as we head into the Merriman presentation next Tuesday.

A key comment made at the Oppenheimer presentation is that that Curis has benefited tremendously by working with Genentech's world class scientists the last six years.

How many small biotechs can say they had access to some of the best scientific talent, in Genentech, and Genentech picks up the tab?